mainly found in lung cancer, breast cancer, pancreatic cancer, and others. The NRG1 gene fusion leads to abnormal activation of signaling pathways through the ERBB family (especially ERBB3 and ERBB2/HER2), which promotes the growth and differentiation of cancer cells. Therefore, targeted therapies...
1.Jonna S, Feldman RA, Swenson J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25:4966-4972. 2.Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NR...
6.Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion–driven lung cancers: the eNRGy1 Global Multicenter Registry. J Clin Oncol. 2021;39(25):2791-2802. doi:10.1200/...
Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S756-S757. doi:10.1016/j.annonc.2023.09.2349 Schram A, Macarulla ...
NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry doi:10.1183/13993003.congress-2019.PA3666Lung cancerBiomarkersGenomicsBackground: NRG1 fusions are potentially actionable driver events enriched in invasive mucinous adenocarcinomas (IMAs). ...
*本图来源于Clinical Cancer Research出版物[11]。3、NRG1介导的信号通路 NRG1通过NRG1/ERBBs信号系统，启动了复杂的细胞内信号级联反应，激活细胞外信号调节激酶（ERK）、磷脂酰肌醇3-激酶（PI3Ks）、丝氨酸/苏氨酸蛋白激酶（AKT）、促分裂原活化蛋白激酶（MAPK）、蛋白激酶C（PKC）和Janus激酶和信号转导转录激活...
LUNG cancerLung cancer persistently leads as the primary cause of morbidity and mortality among malignancies. A notable increase in the prevalence of lung adenocarcinoma has become evident in recent years. Although targeted therapies have shown in treating certain subsets of n...
"ALK and NRG1 fusions coexist in a patient with signet ring cell lung adenocarcinoma." Journal of Thoracic Oncology 12.10 (2017): e161-e163.[3] Cheema, Parneet K., Mark Doherty, and Ming-Sound Tsao. "A case of invasive mucinous pulmonary adenocarcinoma with a CD74-NRG1 fusion protein ...
1.Jonna S, Feldman RA, Swenson J, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25:4966-4972. 2.Drilon A, Duruisseaux M, Han JY, et al. Clinicopathologic features and response to therapy of NRG1 fusion-driven lung cancers: The eNRGy1 Global Multicent...
Schram A, Goto K, Kim D-W, et al. Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion-positive (NRG1+) non-small cell lung cancer (NSCLC). Ann Oncol. 2023;34(suppl 2):S756-S757. doi:10.1016/j.annonc.2023.09.2349 ...